日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.

硼替佐米和氯法拉滨联合治疗难治性肿瘤成人患者的 I 期试验。

Ahmed Jibran, DeSouza Andre, Kummar Shivaani, Rubinstein Lawrence, O'Sullivan-Coyne Geraldine, Govindharajulu Jeevan, Herrick William, Ferry-Galow Kate, Li Li, Wilsker Deborah F, Hogu Murielle, Piekarz Richard, Meehan Robert, Salkeni Mohamad Adham, Shin Sarah, Miller Brandon, Zlott Jennifer, Juwara Lamin, Gray Karen, Kuhlmann Laura, Srivastava Apurva, Parchment Ralph E, Doroshow James H, Takebe Naoko, Chen Alice P

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Selumetinib治疗成人NF1合并不可手术的丛状神经纤维瘤:一项II期试验

Gross, Andrea M; O'Sullivan Coyne, Geraldine; Dombi, Eva; Tibery, Cecilia; Herrick, William G; Martin, Staci; Angus, Steven P; Shern, Jack F; Rhodes, Steven D; Foster, Jared C; Rubinstein, Larry V; Baldwin, Andrea; Davis, Christopher; Dixon, Shelley A H; Fagan, Margaret; Ong, Mary Jane; Wolters, Pamela L; Tamula, Mary Anne; Reid, Olivia; Sankaran, Hari; Fang, Fang; Govindharajulu, Jeevan Prasaad; Browne, Alice T; Kaplan, Rosandra N; Heisey, Kara; On, Thomas J; Xuei, Xiaoling; Zhang, Xiyuan; Johnson, Barry C; Parchment, Ralph E; Clapp, D Wade; Srivastava, Apurva K; Doroshow, James H; Chen, Alice P; Widemann, Brigitte C

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers

一项评估重组白细胞介素-15联合纳武利尤单抗和伊匹木单抗治疗难治性癌症患者的安全性、初步疗效和药效学的I期研究

Ahmed, Jibran; O'Sullivan Coyne, Geraldine; Rubinstein, Larry V; Shin, Sarah J; Takebe, Naoko; Bruns, Ashley; Augustine, Brooke; Mukherjee, Jessica; Ma, Ning; Fino, Kristin; Fung, King Leung; Ferry-Galow, Katherine V; Johnson, Barry C; Parchment, Ralph E; Streicher, Howard; Doroshow, James H; Chen, Alice P

A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

尼洛替尼联合紫杉醇治疗晚期实体瘤患者的I期研究

Shin, Sarah J; O'Sullivan Coyne, Geraldine; Kummar, Shivaani; Miller, Sarah B; Johnson, Barry C; Anderson, Larry; Rubinstein, Larry; Miller, Brandon; Wilsker, Deborah F; Ferry-Galow, Katherine V; Piekarz, Richard; Zlott, Jennifer; Hogu, Murielle; Juwara, Lamin; Krushkal, Julia; Konaté, Mariam; Palmisano, Alida; Zhao, Yingdong; Collins, Jerry; Parchment, Ralph E; Doroshow, James H; Chen, Alice P

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

Berzosertib(一种共济失调毛细血管扩张症相关抑制剂)和 Veliparib(一种口服聚(ADP-核糖)聚合酶抑制剂)联合顺铂治疗难治性实体瘤患者的安全性和耐受性

O'Sullivan Coyne, Geraldine; Do, Khanh T; Kummar, Shivaani; Piha-Paul, Sarina; Rubinstein, Lawrence; Kinders, Robert; Parchment, Ralph E; Wilsker, Deborah; Ferry-Galow, Katherine; Miller, Brandon; Takebe, Naoko; Juwara, Lamin; Ong, Mary Jane; Bruns, Ashley; Hogu, Murielle; Naqash, Abdul Rafeh; Mittra, Arjun; Voth, Andrea Regier; Doroshow, James H; Chen, Alice P

Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells.

强效铁死亡诱导剂 RSL3 可诱导癌细胞中焦亡特异性 gasdermin 的裂解

Herrick William G, Tran Huong-Lan, Tomaino Francesca R, Beall Brittany, Govindharajulu Jeevan, Esposito Dominic, Kuhlmann Laura, Parchment Ralph E, Doroshow James H, Srivastava Apurva K

A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

一项针对难治性实体瘤患者的口服5-氟-2'-脱氧胞苷联合四氢尿苷的I期研究

Chen, Alice P; Kummar, Shivaani; Rubinstein, Larry; Zlott, Jennifer; Coyne, Geraldine O'Sullivan; Chung, Vincent; Newman, Edward M; Lenz, Heinz-Josef; Kelly, Karen; Villaruz, Liza C; Konaté, Mariam M; Ferry-Galow, Katherine V; Wang, Lihua; Kinders, Robert J; Parchment, Ralph E; Covey, Joseph M; Holleran, Julianne L; Piekarz, Richard L; Miller, Sarah B; Juwara, Lamin; Beumer, Jan H; Doroshow, James H

IMMU-12. TRANSLATING COMBINED PD1 AND LAG3 INHIBITION FROM PRECLINICAL MODELS TO PATIENTS WITH REFRACTORY, DNA REPLICATION REPAIR DEFICIENT (RRD) GLIOBLASTOMA: AN IRRDC STUDY

IMMU-12. 将PD1和LAG3联合抑制疗法从临床前模型转化到难治性DNA复制修复缺陷(RRD)胶质母细胞瘤患者:一项IRRDC研究

Behrsing, Holger P; Furniss, Michael J; Davis, Myrtle; Tomaszewski, Joseph E; Parchment, Ralph E; Das, Anirban; Crump, Owen; Kos, Olha; Nunes, Nuno; Stengs, Lucie; Li, Amanda; Levine, Adrian; Nakano, Yoshiko; Friedman, Hope; O’Flaherty, Katharine; Stein, Alexander; Abebe-Campino, Gadi; Bronsema, Annika; Bianchi, Vanessa; Edwards, Melissa; Zacharoulis, Stergios; Ertl-Wagner, Birgit; Morgenstern, Daniel; Pugh, Trevor; Ohashi, Pamela; Bouffet, Eric; Hawkins, Cynthia; Dirks, Peter; Tabori, Uri

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

药物治疗后 HDAC 和 SIRT 基因表达变化与癌细胞系对激酶抑制剂敏感性的关联

Krushkal, Julia; Zhao, Yingdong; Roney, Kyle; Zhu, Weimin; Brooks, Alan; Wilsker, Deborah; Parchment, Ralph E; McShane, Lisa M; Doroshow, James H

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

PARP抑制剂他拉唑帕尼(MDV3800,BMN 673)在BRCA突变晚期实体瘤患者中的药效学作用

Mittra, Arjun; Coyne, Geraldine H O' Sullivan; Zlott, Jennifer; Kummar, Shivaani; Meehan, Robert; Rubinstein, Lawrence; Juwara, Lamin; Wilsker, Deborah; Ji, Jiuping; Miller, Brandon; Navas, Tony; Ferry-Galow, Katherine V; Voth, Andrea Regier; Chang, Ting-Chia; Jiwani, Shahanawaz; Parchment, Ralph E; Doroshow, James H; Chen, Alice P